Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.

Nehal IslamPauline ReynierAntonios DourosOriana H Y YuKristian B Filion

Published in: Diabetes, obesity & metabolism (2023)

Sulphonylureas are associated with an increased risk of VA when used as first-line therapy for type 2 diabetes relative to metformin use. This increased risk should be considered when prescribing sulphonylureas as an initial treatment for type 2 diabetes.

Keyphrases

type diabetes
glycemic control
primary care
cardiovascular disease
heart failure
insulin resistance
left ventricular
congenital heart disease
adverse drug
adipose tissue
skeletal muscle
catheter ablation